Survival Boost
Judy Siegel-Itzkovich, THE JERUSALEM POST
The monoclonal antibody drug Rutiximab (commercially known as Mabtera) has been shown to reduce mortality by an amazing 40 percent in follicular lymphoma patients; 400 new cases are diagnosed each year.
This was proven in research at the Rabin Medical Center-Beilinson Campus that was published recently in the prestigious Journal of the [US] National Cancer Institute.
The meta-analysis of a number of previous controlled studies included Mabtera treatment on 985 patients who were followed up for three years. Dr. Liat Vital of the Davidoff Cancer Center on the Petah Tikva campus said most patients with this kind of blood cancer have relapses.
If this immunological treatment is given following chemotherapy, she added, survival rates soar. Prof. Ofer Sperling, head of the hematology department there, said such patients should receive Mabtera for two years after a relapse of the lymphoma and that it should become standard treatment for all cases. The Rabin Medical Center research, he continued, will help lengthen the survival of many patients around the world.
Related Articles
Painless Robotic Surgery
A distinguished heart surgeon
from Rabin Medical Center
in Israel visited South Florida in
April to discuss with the medical
community new technologies in
minimally invasive heart surgery
using robotics, so that patients
may resume activities within
three days.
Pain and the Relation to Treatment with Cannabis
50-80% of people with Parkinson's disease suffer from a specific type of pain, which until today has not been diagnosed and treated as a general part of this disease.
Rabin Doctors Examine Link Between Asthma and Migraines
Dr. Yael Graif of the Allergy and Immunology Clinic at Israel’s Rabin Medical Center’s Pulmonary Institute recently led a study examining the link between asthma and migraines.